B

Bristol Myers Squibb

Makes drugs for cancer, blood and immune diseases

Executive Director - Chief of Staff, Global Development Operations

Full-TimePosted on 10/20/2026Deadline 12/31/26
No salary listed
Expert
Bachelor's, Master's, MBA, PhD
Uxbridge, UK+1 moreMore locations: Boudry, Switzerland
In Person
Business & StrategyBusiness Operations

About the job

Requirements
  • Deep clinical development and/or global clinical trial operations experience is strongly preferred, including understanding end-to-end trial execution, country and site delivery, and cross-functional interfaces.
  • A degree in Life Sciences or Business Management, and/or an advanced degree in a related discipline, is preferred; examples include a PhD, MS, or MBA.
  • 10–15 years of pharmaceutical industry experience is preferred.
  • Business operations experience and familiarity with divisional management are preferred.
  • Demonstrated people leadership experience, including hiring, developing, and leading direct reports in a global, matrixed organization.
  • Experience as a Chief of Staff, and experience with portfolio management and reporting.
  • Experience developing portfolio and program strategy.
  • Experience leading or supporting large-scale organizational transformation and change, ideally including new operating model design and adoption of digital or AI-enabled ways of working.
  • Experience operating across a global footprint, with awareness of regional and country-level delivery, regulatory, and quality considerations.
  • Understanding of the drug development process and the roles each function plays in program design and execution.
  • Strength in partnering with business leaders to assess critical needs and performance, develop and manage plans and initiatives, and deliver business outcomes.
  • Ability to work in an agile environment and structure vaguely defined problems using creative, pragmatic problem-solving approaches.
  • Strong verbal and written communication skills and change and stakeholder management skills.
  • Ability to build relationships, influence, and drive organizational engagement across functions and sites.
  • Ability to interface effectively with a broad range of internal and external stakeholders at all organizational levels.
  • Influencing and negotiating capabilities in a matrix environment.
  • Project management and execution skills, including managing multiple projects, prioritizing, and planning and conducting projects in a multidisciplinary environment.
Responsibilities
  • Act as a trusted advisor and thought partner to the GDO Head and GDO Leadership Team, helping shape strategy, priorities, and key decisions.
  • Drive development of the GDO strategy and roadmap, annual objectives, and enterprise alignment with Drug Development leadership, BMS leadership, and the Board of Directors as needed.
  • Identify delivery risks, trade-offs, and opportunities across the portfolio and global footprint, and frame strategic options.
  • Provide end-to-end visibility across the delivery continuum, from study start-up through close-out, for early and late development.
  • Establish a single source of truth from the frontline to leadership, with consistent delivery metrics on timelines, enrollment, quality, and cost.
  • Assess delivery status, risks, and systemic execution challenges across therapeutic areas and countries.
  • Lead and facilitate prioritization and resource allocation in partnership with Portfolio Strategy Implementation and Reporting, Development Finance, and Business Insights and Analytics.
  • Ensure country enrollment and footprint decisions align with enterprise strategy, resourcing, and long-range financial plans.
  • Convert strategic priorities into integrated, actionable plans across GDO functions, therapeutic areas, and regions.
  • Drive execution of the GDO transformation roadmap, including moving Global Trial Managers and Global Trial Leaders into therapeutic-area-aligned teams, building therapeutic-area depth in Tier 1 countries, and establishing a centralized risk, compliance, and trial enablement Center of Excellence.
  • Partner with Transformation & Innovation Operations to embed AI-enabled ways of working and retire manual processes.
  • Track progress against objectives and milestones, ensuring risk mitigation, contingency planning, and accountability.
  • Enable execution of integrated Drug Development strategies across Project Leaders, Trial Leadership, and project management.
  • Lead the GDO Leadership Team agenda, governance, and operating rhythm, focusing on high-value topics and strategic decisions while tracking execution against transformation milestones.
  • Lead workstreams or initiatives to solve challenges within GDO or across the organization, including establishing single points of accountability across the delivery continuum.
  • Partner with Portfolio Strategy Implementation and Reporting and stakeholders to optimize governance forums and decision quality.
  • Orchestrate leadership communications across a large, globally distributed organization, including town halls, key messaging, and change and transformation communications.
  • Strengthen team effectiveness, alignment, and follow-through across the GDO Leadership Team.
  • Manage stakeholder relationships across Drug Development, therapeutic areas, regions, and the enterprise, positioning GDO as a partner of choice for sites and patients.
  • Lead, develop, and inspire direct reports covering business operations, strategic initiatives, and communications; set objectives, coach for growth, and build succession strength.
  • Build an inclusive, high-performing team culture that models GDO values and ways of working across a globally distributed organization.
  • Allocate team capacity against high-value priorities and transformation workstreams, ensuring quality and timely output to the GDO Head and GDO Leadership Team.
  • Operate across multiple regions, countries, and time zones to align stakeholders and drive outcomes without formal authority.
  • Represent the GDO Head credibly in key discussions.
Desired Qualifications
  • Deep clinical development and/or global clinical trial operations experience.
  • A degree in Life Sciences or Business Management, and/or an advanced degree in a related discipline; examples include a PhD, MS, or MBA.
  • 10–15 years of pharmaceutical industry experience.
  • Business operations experience and familiarity with divisional management.

About the company

Bristol Myers Squibb discovers, develops and sells prescription medicines for serious illnesses, including cancer, blood disorders, immune diseases and heart disease, for patients treated by doctors and hospitals around the world. Its best-known drug is Opdivo, an immunotherapy that helps the body's own immune system find and attack many kinds of cancer. Researchers develop drug candidates in its labs or bring them in through acquisitions and partnerships, then test them in clinical trials to win regulatory approval. The company makes and markets the approved medicines and earns its revenue from sales of patent-protected drugs. Its roots go back to a business founded in 1887, and it is based in Lawrence Township, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lawrence Township, New Jersey

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are beating forecasts: BMS raised 2026 revenue guidance to $49 billion to $50 billion in July 2026.
  • Newer drugs carry the business: they made $7.6 billion of $13.0 billion in sales in the June 2026 quarter.
  • Manufacturing careers are expanding: a $2.3 billion Houston campus announced in August 2026 will add nearly 500 skilled roles.

What critics are saying

  • Job security is shaky: BMS added 265 New Jersey layoffs in September 2026, bringing its 2026 state cuts to 718.
  • A patent cliff looms: Eliquis and Opdivo, its two biggest drugs, lose US exclusivity around 2028.
  • Older drugs are shrinking fast: Revlimid sales fell 49% to $425 million in the June 2026 quarter as generics spread.

What makes Bristol Myers Squibb unique

  • BMS owns a psychiatry first: Cobenfy treats schizophrenia without blocking dopamine, unlike antipsychotics used for decades.
  • Its top seller is shared: BMS splits Eliquis blood thinner profits roughly equally with Pfizer in most markets.
  • BMS reengineers patients' own immune cells: it sells two CAR T therapies, Breyanzi and Abecma, for blood cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

8%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Oct 23rd, 2026
Three defensive stocks to buy as AI selloff hits: BMY, Colgate and Gilead offer dividends

As investors question the costs and returns of the AI boom, some are turning to defensive stocks in healthcare and consumer goods. Three that pay quarterly dividends stand out: Bristol Myers Squibb, Colgate-Palmolive, and Gilead Sciences. Bristol Myers Squibb shares are up 14.3% this year, with a forward dividend yield of 4.3% and 18 straight years of increases. Second-quarter revenue reached $13 billion, with newer products making up nearly 60%. Colgate-Palmolive is up 20.2% this year and has raised its dividend for 64 years in a row. It reported second-quarter revenue of $5.36 billion. Gilead shares have gained 26%, against 13% for the S&P 500. Second-quarter HIV sales rose 12% to $5.7 billion.

Market Chameleon
Oct 19th, 2026
Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026.

Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026. 19 October 2026, 8:50 AM By Market Chameleon Produced with AI assistance and reviewed by Market Chameleon staff. Bristol Myers Squibb (BMY) said it will present new data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) 2026 Congress (October 23-27 in Madrid), spanning 12 oral presentations and nearly 60 disclosures. The company's update spotlights multiple modalities across solid tumors, including late-breaking Phase 3 studies for izalontamab brengitecan (iza-bren) and late-breaking global Phase 2 data for pumitamig, alongside long-term survival results for Opdivo plus Yervoy. ESMO 2026 presence emphasizes late-breaking Phase 3 and Phase 2 catalysts across solid tumors. In the announcement, Bristol Myers highlighted two late-breaking, Phase 3 studies of izalontamab brengitecan (iza-bren), described as a potential first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01).

Savills
Oct 14th, 2026
San diego Q3 2026 life sciences market report.

San diego Q3 2026 life sciences market report. 14 October 2026 Market highlights. * Overall vacancy increased 60 basis points year over year to 28.5% in Q3 2026, up from 27.9% in Q3 2025. The increase was driven by direct vacancy, which rose to 25.8%, while sublease vacancy declined to 2.8%. * Venture capital funding slowed considerably in 2026, with $1.4 billion raised across 113 deals through Q3, down 34.1% year over year and marking the lowest Q1 through Q3 total since 2022. * Alexandria Real Estate delivered a 427,000-square-foot R&D hub for Bristol Myers Squibb at Campus Point, establishing the company as an anchor tenant at the 2.9- million-square-foot life sciences campus.

Yahoo Finance
Oct 13th, 2026
Eli Lilly beats Bristol Myers Squibb on growth: $65.2B revenue, 45% rise vs. $48.2B

A comparison of Bristol Myers Squibb and Eli Lilly concludes that Lilly is the better healthcare stock to buy in 2026, even at a premium. Lilly's 2025 revenue rose about 45% to $65.2 billion, with net income near $21 billion. Bristol Myers' revenue slipped 0.2% to $48.2 billion, though it returned to a net income of $7.1 billion after an $8.9 billion loss in 2024. Lilly trades at 33.8 times forward earnings against 8.2 times for Bristol Myers. The article says Bristol Myers is cheap for good reason, citing pricing pressure, patent expiries, and an unpredictable recovery. Lilly's weight-loss drugs Zepbound and Mounjaro are expected to lift 2026 revenue above 30%, to $88.6 billion. Bristol Myers is forecast to grow 3% to $49.9 billion.

Chinese LGZ
Oct 9th, 2026
Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility.

Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility. Source link: https://houston365.info/2026/10/09/bristol-myers-squibb-unveils-2-3-billion-investment-in-cutting-edge-houston-pharma-facility/ Bristol Myers Squibb strengthens Houston's life sciences sector with $2.3 billion facility. Bristol Myers Squibb is set to transform Houston's pharmaceutical landscape through a landmark $2.3 billion investment in a cutting-edge manufacturing plant. This initiative, developed in collaboration with the Greater Houston Partnership, aims to elevate the company's production capabilities while cementing Houston's status as a burgeoning center for biopharmaceutical innovation. The project is projected to generate hundreds of skilled jobs and stimulate substantial economic growth within the region. Project overview and strategic importance. The new facility will incorporate the latest manufacturing technologies to optimize efficiency and product quality. With over 1,200 new roles anticipated in scientific research, engineering, and production, the plant will serve as a catalyst for workforce development and community engagement. This expansion aligns with Bristol Myers Squibb's vision to accelerate the delivery of novel therapies and reinforces Houston's growing influence in the life sciences ecosystem. * Innovative manufacturing processes: Adoption of advanced automation and quality control systems. * Employment opportunities: Creation of more than 1,200 specialized jobs across multiple disciplines. * Community collaboration: Strengthening partnerships with local universities and healthcare institutions to foster innovation. | Investment Detail | Information | | Total... | - - Author: Samuel Brown Publish date: 2026-10-09 15:23:00 Copyright for syndicated content belongs to the linked Source. - - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8